Basic HTML Version
© The Canadian Journal of Urology™; 18(Supplement 1); April 2011
Some other prechemotherapeutic drugs are coming
to market for the management of castrate-resistant
prostate cancer. There is also an immunologic approach
to the metastatic cancer. Sipuleucel-T, an autologous
cellular immunotherapy that stimulates a patient’s
immune system to target and attack prostate cancer,
has been shown to increase survival by 4.1 months,
with an average cost of approximately $100,000.
13
Many ongoing studies are aimed at increasing
survival inmenwith prostate cancer who have escaped
hormonal control (become castrate-resistant). These
are usually men diagnosed with a locally advanced
cancer or men who did not accept or could not tolerate
a “primary cure” option or men who underwent a
primary cure but had a recurrence of prostate cancer
that could not be treated with salvage therapy.
Conclusion
The keymessage for physicians is to utilize one or more
of the PSA tools to help diagnose prostate cancer at an
early stage when they can offer the patient aggressive
“curative” therapy while still providing the best long
term quality of life and the least chance of failure -- in
the right patient at the right time.
Disclosure
Dr. Jack Barkin is an active urologist and Chief of Staff
at the Humber River Regional Hospital in Toronto.
He sits on the medical advisory board for Abbott,
AstraZeneca, Bayer, Boehringer-Ingelheim, Eli Lilly,
GlaxoSmithKline, Merck Frosst, Paladin, Pfizer, sanofi-
aventis and Solvay. He has done the clinical research
onAndrogel, Avodart, Casodex, Cialis, Detrol, Flomax,
Hytrin, Levitra, Xatral, Proscar and Viagra. He has
spoken all over the world for all of the companies
outlined.
23
References
1. Sakr WA, Grignon DJ, Haas GP, Heilbrun LK, Pontes
JE, Crissman JD. Age and racial distribution of prostatic
intraepithelial neoplasia.
Eur Urol
1996;30(2):138-144.
2. Shariat SF, Roehrborn CG. Using biopsy to detect prostate
cancer.
Rev Urol
2008;10(4):262–280.
3. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of
prostate cancer amongmenwith a prostate-specific antigen level
<or =4.0 ng per milliliter.
N Engl J Med
2004;350(22):2239-2246.
4. Richardson TD, Oesterling JE. Age-specific reference ranges
for serum prostate-specific antigen.
Urol Clin North Am
1997;24(2):339-351.
5. Nakanishi H, Groskopf J, Fritsche HA et al. PCA3 molecular
urine assay correlates with prostate cancer tumor volume:
implication in selecting candidates for active surveillance.
J Urol
2008;179(5):1804-1809.
6. Schroder FH, Hugosson J, Roobol MJ et al. Screening and
prostate cancer mortality in a randomized European study.
N
Engl J Med
2009;360(13):1320-1328.
7. Andriole GL, Grubb RL 3
rd
, Buys SS et al. Mortality results from
a randomized prostate-cancer screening trial.
N Engl J Med
2009;360(13):1310-1319.
8. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw
A. Clinical results of long-term follow-up of a large, active
surveillance cohort with localized prostate cancer.
J Clin Oncol
2010;28(1):126-131.
9. American Urology Association. Prostate-specific antigen best
practice statement: 2009 update. Available: www.auanet.org/
content/guidelines-and-quality-care/clinical-guidelines/main-
reports/psa09.pdf.
10. American Cancer Society. Can prostate cancer be found
early? Available: www.cancer.org/Cancer/ProstateCancer/
DetailedGuide/prostate-cancer-detection
11. Barkin J. High intensity focused ultrasound (HIFU).
Can J Urol
2011;18(2):5634-5643.
12. Liu XS, Folia C, Gomella LG. Pharmacology for common
urologic diseases: 2011 review for the primary care physician.
Can J Urol
2011;18(Suppl 1):24-38.
13. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T
immunotherapy for castration-resistant prostate cancer.
N Engl
J Med
2010;363(5):411-422.
PSA and the family physician